Bacterial Infections Clinical Trial
— SELF-OPATOfficial title:
Self-administration in Outpatient Parenteral Antimicriobial Therapy Service
Home Outpatient Parenteral Antimicrobial Treatment (Home-OPAT) is a service provided to patients that receive antibiotics via infusion but are clinically well enough to go home. A nurse will visit the patient daily to administer the antibiotics. However, the patient or a caregiver can also administer the antibiotics without the help of a nurse. This is called Self-OPAT. The Self-OPAT service is already in practice internationally but not yet in the Netherlands. The goal of this observational study is to assess the possibility to implement Self-OPAT in the Dutch context. The main questions it aims to answer are: Which patients are suitable for Self-OPAT services? How can patients be trained adequately for performing Self-OPAT? What are the experiences of patients with Self-OPAT? How much nurse engagement is needed during Self-OPAT? Is the outcome of treatment with Self-OPAT comparable to Home-OPAT? How do the costs of Self-OPAT differ from the costs of Home-OPAT? How can you implement an Self-OPAT program in the hospital? Participants will be trained by a nurse to administer the infusion antibiotics. They will then administer the antibiotics themselves for as long as the duration of treatment. Every week a nurse will visit to check the progression of the treatment and check the functioning and hygiene of the infusion materials. After a month participants will fill-out a questionnaire about their experience with Self-OPAT.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | March 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged 18 and over - Hospitalized - Treated with intravenous antimicrobial therapy and to be discharged with OPAT service - To be discharged with OPAT service for a minimum of 5 days - Central intravenous access/line in place - Has a safe home environment (water, telephone, refrigerator available) and access to transport to hospital - Able to understand written information and able to give informed consent - Able and willing to perform self-administration, or able and willing to be self-administered by family members or other caregivers - Able and willing to fill in questionnaires Exclusion Criteria: - Former participation in this study - Pregnancy - Discharge to a rehabilitation centre or nursing care centre (i.e. no discharge to home) - Concomitant nursing care, if the patient requires other nursing care the patient will be placed on nursing care and the nurses administer the medication during the concomitant nursing care - More than two intravenous drugs required - More than one intravenous administration device required (e.g. elastomeric pump and medication cassette) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amphia hospital | Breda | Noord-Brabant |
Netherlands | Erasmus MC | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center | Amphia Hospital |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Duration of training | Duration of S-OPAT training | 30 days after discharge | |
Other | Patient satisfaction with training | The patients or caregivers who followed the S-OPAT training will receive a questionnaire with questions about their experience with the training and how well they understood the training. | 30 days after discharge | |
Other | Difference between S-OPAT carried out by patient or caregiver | The performance of self-administration in the S-OPAT services by patients and caregivers will be compared. | 30 days after discharge | |
Primary | To asses the capability of patients to self-administer antibiotics in the outpatient setting in the Dutch medical system. | To assess the feasibility of self-administration of intravenous antimicrobial therapy in the Dutch context. Feasibility is defined as adherence to the study protocol, which is defined as qualification for S-OPAT after training and completing an S-OPAT trajectory with a weekly scheduled nurse visit. | 30 days after discharge | |
Secondary | Visits | To investigate the number of scheduled and unscheduled S-OPAT related nurse visits to the patient | 30 days after discharge | |
Secondary | Consultations | To investigate the number of OPAT related telephone consultations (to the nurse and the hospital) | 30 days after discharge | |
Secondary | Devices | To investigate the number of the different infusion devices (i.e. elastomeric pumps, infusion bags, infusion cassettes) used for S-OPAT patients in this study | 30 days after discharge | |
Secondary | Time to discharge | To investigate the time to discharge after signing up for OPAT | 30 days after discharge | |
Secondary | Training completion | The number of patients/caregivers who successfully complete S-OPAT training and are therefore qualified for self-administration. | 30 days after discharge | |
Secondary | Patient/caregiver characteristics | To describe characteristics of patients/caregivers who successfully completed S-OPAT training versus patients who did not qualify for self-administration.
To describe characteristics of patients/caregivers who successfully completed their S-OPAT trajectory (with only a weekly scheduled nurse visit) versus patients who did not. |
30 days after discharge | |
Secondary | The number of patients/caregivers who finish their complete assigned S-OPAT trajectory | The total amount of patients or caregivers that succesfully complete their assigned S-OPAT trajectory. | 30 days after discharge | |
Secondary | The costs associated with performing and organizing S-OPAT in de Dutch medical system | To investigate the healthcare costs of S-OPAT by investigating the costs attributed to:
loss of productive hours by the patient requirement of nursing staff travel costs cost of materials |
30 days after discharge | |
Secondary | Clinical outcomes: The outcomes of the infection in S-OPAT treatment | To investigate the progression of the infection in the patients when in S-OPAT treatment. | 30 days after discharge | |
Secondary | Clinical outcomes: Amount of patients experiencing reinfection in S-OPAT treatment | To investigate the amount of patients that experience reinfection when treated in S-OPAT setting | 30 days after discharge | |
Secondary | Clinical outcomes: Duration of treatment in S-OPAT | To investigate the amount of time patients spend in S-OPAT treatment | 30 days after discharge | |
Secondary | Clinical outcomes: Patient mortality as performing S-OPAT | To investigate how many patients die whilst performing S-OPAT | 30 days after discharge | |
Secondary | Adverse events | To investigate the adverse events reported during the first 30 days after discharge. | 30 days after discharge | |
Secondary | Readmission rate | To investigate the 30 day all-cause readmission rate after the end of the S-OPAT trajectory.
To investigate the 30 day OPAT/infection related readmission rate of the S-OPAT trajectory |
30 days after discharge | |
Secondary | Satisfaction outcomes | To investigate the patient acceptability with S-OPAT by handing them a questionnaire about their experience with S-OPAT. | 30 days after discharge | |
Secondary | Health outcomes | The patients will fill out a EQ-5D-5L questionnaire both at discharge and after 30 days of S-OPAT treatment. These will be compared to each other and to other patients. | 30 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |